Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : $128.0 million
Deal Type : Acquisition
Ligand to Acquire APEIRON Biologics AG for $100 Million
Details : Ligand acquires Apeiron Biologics pipeline which also includes Qarziba (dinutuximab beta), it is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above.
Product Name : Qarziba
Product Type : Antibody
Upfront Cash : $100.0 million
August 07, 2024
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : $128.0 million
Deal Type : Acquisition
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
APEIRON Respiratory Therapies Announces Positive Results From Phase I Trial of Inhaled APN01
Details : The study met all primary and secondary endpoints, with all results indicating that the inhalation of APN01 (alunacedase alfa) at all dosage levels used in the trial is safe and well tolerated.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apeiron Biologics Begins Phase 1 Trial to Treat Covid-19 with Inhaled APN01
Details : Primary study objective is the evaluation of safety and tolerability of single ascending doses (SADs) and multiple ascending doses (MADs) of inhaled APN01 when administered via a jet nebulizer in healthy subjects.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SNS-301,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Sensei Biotherapeutics
Deal Size : $30.0 million
Deal Type : Series B Financing
Details : Sensei’s lead ImmunoPhage product candidate, SNS301, is being evaluated in a Phase 1/2 trial for the treatment of locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
November 01, 2021
Lead Product(s) : SNS-301,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Sensei Biotherapeutics
Deal Size : $30.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Apeiron Respiratory Therapies GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 04, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Apeiron Respiratory Therapies GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNC210
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Recipient : Neuphoria Therapeutics
Deal Size : Undisclosed
Deal Type : Financing
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial
Details : Under the Subscription Agreement dated 2 June 2020 with Apeiron, Apeiron agreed to recapitalise the Company and assist in securing further equity capital to fund the Company's BNC210 Phase 2b Clinical trial for the treatment of post-traumatic stress diso...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 02, 2021
Lead Product(s) : BNC210
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Recipient : Neuphoria Therapeutics
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 25, 2020
Lead Product(s) : Alunacedase Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expansion of APEIRON Biologics and Domainex Partnership will Advance Cancer Drug Discovery
Details : Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 11, 2020
APEIRON Biologics and MaxCyte Enter Into Clinical and Commercial Licensing Agreement for APN401
Details : Under the terms of this licensing agreement, APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
July 07, 2020
Lead Product(s) : RhACE2 APN01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : RhACE2 APN01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable